This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): estradiol + progestogen gel
Description: Bio-E/P-Gel is a estradiol + progestogen combination transdermal hormone therapy gel product.
Deal Structure: In June 2000, Biosante entered into a license agreement with Antares Pharma IPL AG pursuant to which Antares granted Biosante an exclusive license to certain proposed hormone therapy products including rights to sublicense the hormone therapy products, in order to develop and market the hormone therapy products in certain territories. The license agreement with Antares required Biosante to pay a $1,000,000 up-front license fee to Antares and to pay royalties to Antares based on a percentage of the net sales of any products Biosante's sublicensees sell incorporating the licensed technology.
In August 2001, Biosante entered into a sublicense agreement with Solvay Pharmaceuticals covering the U.S. and Canadian rights to the estrogen/progestogen combination transdermal hormone therapy gel product licensed from Antares. Under the terms of the agreement, Solvay sublicensed the estrogen/progestogen combination transdermal hormone therapy gel product for an initial payment of $2.5...See full deal structure in Biomedtracker
Partners: ANI Pharmaceuticals, Inc. Antares Pharma, Inc.
Pink Sheet FDA Performance Tracker: User Fee Goal Dates
Additional information available to subscribers only: